Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia
Tóm tắt
To determine the steady-state trough serum and epithelial lining fluid (ELF) concentrations of teicoplanin 12 mg/kg per day in critically ill patients with ventilator associated pneumonia. Prospective, pharmacokinetic study in the surgical intensive care unit in a university hospital. Thirteen adult patients with nosocomial bacterial pneumonia on mechanical ventilation were enrolled. All subjects received a 30-min intravenous infusion of 12 mg/kg teicoplanin every 12 h for 2 consecutive days followed by 12 mg/kg once daily. Teicoplanin concentrations in serum and ELF were determined simultaneously 4–6 days after antibiotic administration started. The median total and free concentrations of teicoplanin in serum at trough were 15.9 μg/ml (range 8.8–29.9) and 3.7 (2.0–5.4), respectively. The concentration in ELF was 4.9 (2.0–11.8). In critically ill patients with ventilator-associated pneumonia the administration of high teicoplanin doses is required to reach sufficient trough antibiotic concentrations in lung tissues at steady state. At that time trough-free concentrations of teicoplanin in serum and ELF are comparable.
Tài liệu tham khảo
Rello J, Diaz E (2003) Pneumonia in the intensive care unit. Crit Care Med 31:2544–2551
Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ (1993) Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 37:1065–1072
Wilson APR (2000) Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 39:167–173
Moreo G, Sardi C, Volpato G, Romeo B, Cavenaghi L (1989) Penetration of teicoplanin into bronchial secretion and respiratory tract tissues. Eur Respir J 2 [Suppl 8]:733S
Baldwin DR, honeybourne D, Wise R (1992) Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 36:1171–1175
Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28:143–160
MacGowan AP (1998) Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 20:473–477
Menichetti F (2005) Current and emerging serious Gram positive infections. Clin Microbiol Infect 11 [Suppl 3]:22–28
Wilson APR, Gruneberg RN, Neu H (1994) A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 4 [Suppl 1]:1–30
Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM (1995) Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 39:1842–1847
Liu P, Mueller M, Derendorf H (2002) Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19:285–290
Pham LH, Brun-Buisson C, Legrand P, Rauss A, Verra F, Brochard L, Lemaire F (1991) Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am Rev Respir Dis 143:1055–1061
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmele T, Chassard D, Saux MC, Allaouchiche B (2004) Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:976–979
Boselli E, Breilh D, Rimmele T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B (2004) Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:989–991
Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B (2003) Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 31:2102–2106
Boselli E, Breilh D, Rimmele T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B (2005) Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 33:1529–1533
Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, Farinotti R, Chastre J, Gibert C (1993) Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37:281–286
Conte JE Jr, Golden JA, Kipps J, Zurlinden E (2002) Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46:1475–1480
Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R (2003) Intrapulmonary penetration of linezolid. J Antimicrob Chemother 51:1431–1434
Harding I, MacGowan AP, White LO, Darsley ERS, Reed V (2000) Teicoplanin therapy for Staphylococcus aureus septicemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 45:835–841